October 2014- Volume 10, Issue 10

October 2014

In this Issue

Preclinical

A printable model for liver disease

A printable model for liver disease

Organovo designs and creates functional, 3D human tissues for medical research and therapeutic applications

Reaching for results

Reaching for results

Seattle Genetics and Genmab create new ADC collaboration, adding to Genmab’s preclinical pipeline

Wiping out C. difficile

Wiping out C. difficile

Synthetic Biologics soon to initiate clinical trials of SYN-004 for deadly C. diff. infections

Sage presents new preclinical data on antiepileptic drug

Sage presents new preclinical data on antiepileptic drug

Data highlighted at Eilat Conference underscore potential of SAGE-217 to address acute and chronic forms of epilepsy and other seizure disorders

Research & Development

Neighbor helping neighbor

Neighbor helping neighbor

Janssen, J&J Innovation serve as catalysts for neuroscience research with University of Toronto on Alzheimer’s disease study

Enter the zebrafish

Enter the zebrafish

CQDM and OCE co-fund neuroscience research collaboration

Two against endometriosis

Two against endometriosis

SRI International and Nobelpharma partner on endometriosis drug development

Getting social to report adverse drug reactions

Getting social to report adverse drug reactions

U.K. agency leads EU project on the use of smartphones and social media for drug safety information

Lucigen and Thermo Fisher team up on next-gen sequencing

Lucigen and Thermo Fisher team up on next-gen sequencing

Lucigen Corp. and Thermo Fisher Scientific announced in late August that they would partner to release new mate pair library technology for Ion Torrent sequencing

Diagnostics

PDI enters molecular diagnostics market

PDI enters molecular diagnostics market

Acquires thyroid and pancreatic cancer tests as first step toward creation of a molecular diagnostics force in Interpace Diagnostics

Collaboration to combat cancer

Collaboration to combat cancer

Team develops molecular diagnostic tests in tandem with targeted therapeutics

Moving to a multiplayer game

Moving to a multiplayer game

Illumina strikes several partnerships to advance oncology diagnostics to panel-based assays

CGI diagnostics added to online test database

CGI diagnostics added to online test database

Genetic Testing Registry now contains 40 of Cancer Genetics’ proprietary tests

Clinical Trials

Nymox’s prostate cancer candidate progressing apace

Nymox’s prostate cancer candidate progressing apace

NX-1207 continues to show an encouraging safety profile in prostate cancer and BPH

A new way to go after breast cancer

A new way to go after breast cancer

Spanish lab finds promise in fighting breast cancer with experimental drug nintedanib

Two is better than one

Two is better than one

Bristol-Myers Squibb, Celgene deliver one-two punch to beat breast cancer

Looking good

Looking good

Clinical trial shows potential for Auxilium’s CCH for treating cellulite

Cognitive computing in the clinic

Cognitive computing in the clinic

Mayo Clinic and IBM to apply Watson to clinical trial enrollment

Business & Government Policy

Delving into duvelisib

Delving into duvelisib

Infinity, AbbVie link up to develop Infinity’s PI3K-delta/gamma inhibitor in oncology

Lysosomal storage disease could be an attractive market

Lysosomal storage disease could be an attractive market

According to Thomson Reuters, there is economic power in ultra-orphan disease therapies

Attaching the umbilical cord

Attaching the umbilical cord

Novartis invests $35M in Gamida Cell with eye on stem cell therapies

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Sitting pretty for $17 billion?

Sitting pretty for $17 billion?

Merck KGaA acquiring Sigma-Aldrich to enhance position in increasingly attractive life-sciences market

Discovery

Aphios scores grant for green drug discovery technology

Aphios scores grant for green drug discovery technology

SBIR grant will fund development of prototype tech to unearth potential therapeutic chemicals in biomass

Brain cells from skin

Brain cells from skin

Researcher awarded £900,000 to develop an innovative new way to screen potential new treatments for diseases such as Alzheimer’s

New agreement with Schrödinger a ‘game-changer’

New agreement with Schrödinger a ‘game-changer’

Schrödinger and Tri-I TDI launch a joint agreement to boost early-stage research by young researchers

Welcome to Discovery Park

Welcome to Discovery Park

New facilities will house drug discovery and bioscience centers

Carving out new cancer territory

Carving out new cancer territory

Blueprint Medicines announces discovery of novel oncology drug targets

Q&A

Q&A: ‘Making cancer history’

Q&A: ‘Making cancer history’

DDNews speaks with Dr. Philip Lorenzi about how MD Anderson Cancer Center guides drug discovery and development via enhanced targets and biomarkers

Feature

A Capitol affair

A Capitol affair

Society for Neuroscience stays in its own backyard for this year’s annual meeting, looking to host more than 30,000 attendees

Editor's Focus

The business of reducing obesity

The business of reducing obesity

The effort to reduce obesity (and to profit from that effort) isn’t anything new, but based on my email inbox recently, perhaps we’re about to enter into an era of blockbuster weight-management medications. For the moment, however, we’re at the early stages of any such race, and it looks like Novo Nordisk and Orexigen are fighting for the strong start out of the gate.

Commentary

Peer review and the life sciences

Peer review and the life sciences

In an era of "publish or perish," combined with "fund or perish," we may be moving toward an era in which peer review is no longer up to the task, and we end up with too many journals and too little rigor

Guest Commentary: Factors impacting genome editing success and failure--A focus on cell lines

Guest Commentary: Factors impacting genome editing success and failure--A focus on cell lines

The ability to create isogenic cell lines in which the genome editing event is the sole differentiator between the phenotypes of two cells is a powerful tool. Despite all the recent developments and improvements in targeting platforms, certain challenges remain, and the role played by the choice of cell line in order to achieve success cannot be overstated.
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022